Eli Lilly Buys Orna Therapeutics for $2.4B and Unveils Monthly Zepbound Pen
Eli Lilly agreed to acquire Orna Therapeutics for $2.4 billion to expand its CAR-T therapeutics platform. It launched a monthly-dose Zepbound pen after competitor CagriSema failed to outperform its GLP-1 obesity drug, reinforcing its 60% U.S. share in a market projected over $100 billion in four years.
1. Orna Therapeutics Acquisition
Eli Lilly has agreed to acquire Orna Therapeutics in a $2.4 billion all-cash transaction, adding Orna’s engineered circular RNA platform to its CAR-T oncology pipeline. The deal expands Lilly’s cell and gene therapy capabilities by integrating Orna’s mRNA constructs aimed at improving antigen targeting and manufacturing efficiency.
2. Zepbound Monthly-Dose Pen Launch
The company launched a monthly-dose pen for Zepbound, its GLP-1 receptor agonist for obesity management, streamlining administration and potentially boosting patient adherence. The new format allows once-monthly subcutaneous injections compared with the prior weekly schedule and leverages pen-injection technology to simplify dosing.
3. Obesity Drug Market Position
Lilly holds approximately 60% of the U.S. GLP-1 obesity drug market, which analysts forecast could exceed $100 billion over the next four years. Competitor Novo Nordisk’s CagriSema failed to demonstrate superior efficacy over Zepbound in recent trials, reinforcing Lilly’s leadership while underscoring competitive pressures from Pfizer and other late-stage entrants.